Kronos Bio Inc KRON

NAS: KRON | ISIN: US50107A1043 2/05/2024

1,030 USD (0,00%)

(0,00%) 2/05/2024

Toon enkel gratis nieuws

18 augustus 2022 · Kronos Bio et Invivoscribe s'associent sur un diagnostic d'accompagnement de l'entosplétinib, le composé expérimental de Kronos Bio développé pour les patients atteints de LMA · Persbericht

16 augustus 2022 · Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational Compound Being Developed for Patients with AML · Persbericht

17 december 2021 · Omega Funds clôture un fonds sursouscrit de 650 millions de dollars, le Fonds VII, pour investir dans des entreprises transformatrices des sciences de la vie · Persbericht

17 december 2021 · Omega Funds Closes Oversubscribed $650 Million Fund VII to Invest in Transformative Life Science Companies · Persbericht

10 maart 2021 · Kronos Bio to Present Pre-Clinical Data at the AACR Virtual Annual Meeting 2021 for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers · Persbericht

4 maart 2021 · Kronos Bio Announces Positive End-of-Phase 2 Meeting with FDA for Entospletinib in Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia (AML) · Persbericht

25 februari 2021 · Kronos Bio Announces First Patient Dosed in Phase 1/2 Clinical Trial of KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers · Persbericht

22 februari 2021 · Kronos Bio Announces Participation in the Cowen 41st Annual Health Care Conference · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe